BYSI - Dosing underway in BeyondSpring's triple combo study of plinabulin in solid tumors

The first patient has been dosed in BeyondSpring's (BYSI) Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy ((RT)).This triple combination is actively recruiting in seven metastatic or locally advanced cancers, which include bladder cancer, melanoma, Merkel cell cancer, MSI-H cancers (of any histology), non-small cell lung cancer ((NSCLC)), renal cell cancer, and small cell lung cancer ((SCLC)). Patients will receive a triple combo treatment until disease progression or development of unacceptable toxicity, withdrawal from study treatment, or discontinuation of this study.Plinabulin will be tested in combination with five different PD-1/PD-L1 immunotherapies (avelumab, durvalumab, nivolumab, atezolizumab and pembrolizumab) and the exact dosing and treatment schedule will be determined by treatment cycle for each immunotherapy agent.The first patient progressed on Keytruda and chemotherapy in first-line NSCLC, and has been dosed with RT, plinabulin (30 mg/m2) and Keytruda.

For further details see:

Dosing underway in BeyondSpring's triple combo study of plinabulin in solid tumors